Neuronal ceroid lipofuscinosis 6

Alternate names

CLN6; Neuronal ceroid lipofuscinosis, Gypsy/Indian early juvenile variant; CLN6 disease, late infantile (subtype); CLN6 disease, adult Kufs type A (subtype)

Definition

CLN6 disease is an inherited disorder that primarily affects the nervous system.

Summary

• CLN6 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease.
• All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability.
• The different NCLs are distinguished by their genetic cause.
• Each disease type is given the designation "CLN," meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.

Onset

The signs and symptoms of this condition typically begin between early and late childhood, but sometimes they can appear in adulthood.

Epidemiology

The incidence of CLN6 disease is unknown; more than 125 cases have been described in the scientific literature. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Cause

Mutations in the CLN6 gene cause CLN6 disease. The CLN6 gene provides instructions for making a protein whose function is not well understood. Within cells, the CLN6 protein is found in a structure called the endoplasmic reticulum, which is involved in protein processing and transport. Research suggests that the CLN6 protein helps cells get rid of materials they no longer need.

Gene mutations

• Most CLN6 gene mutations result in the production of an abnormal CLN6 protein that is quickly broken down (degraded). As a result, there is a severe reduction in the amount of functional CLN6 protein in cells. While it is not known how the loss of this protein causes the signs and symptoms of CLN6 disease, it is likely that the protein's quick degradation contributes to the childhood onset of CLN6 disease.
• In the cases in which CLN6 disease develops in adulthood, CLN6 gene mutations often result in a CLN6 protein with reduced function.
• Research suggests that these CLN6 gene mutations allow enough functional protein to be produced so that signs and symptoms of the disorder do not develop until later in life.

• CLN6 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes, which are cell structures that digest and recycle different types of molecules.
• These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects.
• The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues leads to the signs and symptoms of CLN6 disease.
• However, it is unclear how mutations in the CLN6 gene are involved in the buildup of substances in lysosomes in CLN6 disease. These accumulations occur in more cells throughout the body in children with CLN6 disease than in affected adults.

Inheritance

Autosomal recessive inheritance, a 25% chance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Signs and symptoms

• Most children with CLN6 disease initially experience the loss of previously acquired skills (developmental regression). Affected individuals can also develop recurrent seizures (epilepsy), difficulty coordinating movements (ataxia), muscle twitches (myoclonus), impaired speech (dysarthria), and vision loss.
• The movement problems worsen over time until affected children cannot walk, stand, or sit without assistance. Intellectual function also declines over time. Most children with CLN6 disease do not survive into adulthood.
• Some people with CLN6 disease do not show signs or symptoms of the condition until adulthood, typically after age 30. These individuals can have epilepsy, ataxia, dysarthria, and a progressive loss of intellectual function.
• CLN6 disease usually does not cause vision loss in affected adults. Adults with this condition do not often survive more than 10 years after diagnosis.

Treatment

Treatment options are limited to therapies that can help relieve some of the symptoms.

NIH genetic and rare disease info

• NIH info on Neuronal ceroid lipofuscinosis 6

Neuronal ceroid lipofuscinosis 6 is a rare disease.

Neuronal ceroid lipofuscinosis 6 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia